Neuronetics (NASDAQ:STIM) will issue its quarterly earnings data before the market opens on Tuesday, March 2nd. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
Neuronetics stock opened at $17.75 on Tuesday. Neuronetics has a one year low of $1.25 and a one year high of $22.43. The business has a fifty day moving average of $16.36 and a two-hundred day moving average of $8.97. The company has a market cap of $336.81 million, a P/E ratio of -10.57 and a beta of 3.05.
Several research firms have recently issued reports on STIM. BTIG Research lifted their price target on Neuronetics from $14.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, January 21st. JMP Securities lifted their price target on Neuronetics from $15.00 to $23.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. William Blair raised Neuronetics from a “market perform” rating to an “outperform” rating in a research note on Friday, January 22nd. Zacks Investment Research raised Neuronetics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 26th. Finally, Piper Sandler lifted their price target on Neuronetics from $20.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, January 21st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Neuronetics currently has a consensus rating of “Buy” and a consensus price target of $16.40.
Neuronetics Company Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.